Figure 2.

(a–f) Anti-CD137 mAb’s block immune complex formation. Kidneys sections from NZB/W F₁ mice at 35 (a, c, and e) and 45 (b, d, and f) weeks of age that had received no treatment (a and b), isotype-matched control mAb’s (c and d), or anti-CD137 mAb’s (e and f) were stained with FITC-goat anti-mouse IgG. (g–j) Anti-CD137 mAb’s block kidney disease. Shown are glomeruli from a BALB/c mouse (g), an untreated NZB/W F₁ mouse (h), an isotype control-treated mouse (i), and an anti-CD137 mAb–treated mouse (j). (k) Disease severity following anti-CD137 mAb treatment. NZB/W F₁ mice were untreated or treated with either isotype-matched control mAb’s or anti-CD137 mAb’s beginning at 14 weeks of age. Disease index was based upon kidney histopathology (see Methods).